Real-world efficacy of faricimab for diabetic macular edema: One year outcomes and evidence of undertreatment

European Journal of Ophthalmology 2026

View at publisher
Authors: George Zelhof, Ticiana Criddle, Philip I. Burgess
DOI: 10.1177/11206721261422313
Cited by: 0

Abstract

AimsTo evaluate the efficacy and durability of faricimab for diabetic macular edema (DME) in a real-world population over 52 weeks using a personalised treatment interval protocol.MethodsRetrospective cohort of centre-involving DME treated with faricimab at St Paul's Eye Unit, Liverpool (September 2022-January 2025). Exclusions: follow-up

Fields of Study & Subjects

Retinal Diseases and Treatments Retinal and Macular Surgery Ocular Diseases and Behçet’s Syndrome

Publication details

Journal / source
European Journal of Ophthalmology
Volume
36
Issue
4
Pages
963–971
Publication date
10 February 2026
Language
EN